The Global Fibromyalgia Treatment Market size is expected to reach $4 billion by 2030, rising at a market growth of 4.4% CAGR during the forecast period.
Muscle Relaxants are widely utilized by people to ease muscle stiffness or spasms and help in relaxing painful knots. As road accidents are increasing, the usage of muscle relaxant is increasing. Therefore, Muscle relaxants accounted for $202.3 million revenue in 2022. Road traffic accidents kill approximately 1.3 million people annually and injure between 20 and 50 million others, as stated by the WHO report. Over fifty percent of road traffic deaths and injuries involve vulnerable road users, such as pedestrians, motorcyclists, cyclists, and passengers. Children and young adults aged 5 to 29 are disproportionately susceptible to road traffic injuries.
Among people of this age, it is the most common cause of death. Males under 25 are more likely than females to be involved in traffic incidents. According to statistics, males account for 73% of the traffic fatalities in this age group. 93% of road traffic fatalities occur in low- and middle-income countries, increasing road traffic injury rates in developing nations. Consequently, the rise in road accidents due to various factors is anticipated to increase the cases of fibromyalgia, which will raise the need for fibromyalgia treatment, thereby driving market expansion. Some of the factors impacting the market are research for novel drugs and possible uses of combination therapy, Co-relation between lupus and fibromyalgia, and non-drug alternative.
Chronic fibromyalgia substantially limits patients' ability to engage in typical social and professional activities and makes maintaining relationships with friends, family, and coworkers difficult. The full spectrum of pain, tiredness, sleep disturbances, and depression symptoms cannot be fully addressed by any available medicines. The growing need for better and more effective treatment options for FM will spur pharmaceutical companies to continue their research and development efforts, driving the market. Lupus is a common (chronic) autoimmune disorder that can be debilitating and has the potential to affect a variety of body systems. Lupus is developed when the immune system, which typically aids in defending the body against infection and disease, targets its tissues. As a result, it is anticipated that their prevalence will rise along with the number of lupus cases, fueling demand for fibromyalgia treatment options and fueling market expansion.
However, Fibromyalgia can be managed with non-drug alternatives with many benefits while incurring no side effects. One such alternative is stress management. This works by creating a strategy to prevent or reduce overexertion and emotional tension and allowing oneself daily relaxation time. This is expected to hamper the market growth in the projected period. Fibromyalgia is reportedly widespread among those who have recovered from COVID-19, according to a study from the National Center for Biotechnology Information (NCBI). This data suggests that fibromyalgia may be more common among those who have had COVID-19, increasing the need for treatment after the pandemic. Hence, the pandemic caused the market to decline, but later, the market started to recover due to the growing number of FM cases.
On the basis of distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies and online providers. The drug stores & retail pharmacies segment witnessed the largest revenue share in the market in 2022. The segment growth is due to the presence of drug stores and retail pharmacies in multiple locations in diverse neighborhoods and communities, which are extensively accessible to the general public. This ubiquitous presence guarantees easy access to drugs and treatments for those with fibromyalgia.
Based on drug class, the market is segmented into antidepressants, anticonvulsants, muscle relaxants and others. The antidepressants segment acquired a substantial revenue share in the market in 2022. This is because there are several antidepressant choices accessible for fibromyalgia patients. Multiple antidepressants are readily available, allowing for greater prescribing flexibility and a greater chance that each patient will receive the right treatment. This market's expansion is also anticipated to be aided by the availability of generic versions of antidepressants approved for use in fibromyalgia patients.
| Report Attribute | Details |
|---|---|
| Market size value in 2022 | USD 2.9 Billion |
| Market size forecast in 2030 | USD 4 Billion |
| Base Year | 2022 |
| Historical Period | 2019 to 2021 |
| Forecast Period | 2023 to 2030 |
| Revenue Growth Rate | CAGR of 4.4% from 2023 to 2030 |
| Number of Pages | 173 |
| Number of Table | 270 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Drug Class, Distribution Channel, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region registered the highest revenue share in the market in 2022. This is due to several variables, including increased fibromyalgia prevalence, new treatment choices, and supporting healthcare infrastructure. A vital healthcare infrastructure, high purchasing power, and increased acceptance of fibromyalgia drugs are anticipated to fuel market expansion. The market in this region is also driven by numerous significant players and developments in manufacturing technology these businesses use to manufacture effective goods.
Free Valuable Insights: Global Fibromyalgia Treatment Market size to reach USD 4 Billion by 2030
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.
By Drug Class
By Distribution Channel
By Geography
The Market size is projected to reach USD 4 billion by 2030.
Research for novel drugs and possible uses of combination therapy are driving the Market in coming years, however, Non-drug alternative restraints the growth of the Market.
AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.
The expected CAGR of this Market is 4.4% from 2023 to 2030.
The Anticonvulsants segment is leading the Global Fibromyalgia Treatment Market by Drug Class in 2022 thereby, achieving a market value of $2 billion by 2030.
The North America market dominated the Global Fibromyalgia Treatment Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.5 billion by 2030.
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
